Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a correction disclosure substantially increasing the contract amount from approx. KRW 242.0B to approx. KRW 517.9B and extending the contract period and disclosure postponement period to December 31, 2033, at the customer’s request regarding the contract manufacturing agreement originally disclosed on May 26, 2025.
📊 [Key Disclosure Details & Financial Figures]
- Original Filing & Submission Date: Single Sales and Supply Contract (Submitted on May 26, 2025)
- Reason for Correction: Change in contract amount and extension of contract period at the customer’s request
- Key Correction Items:
- Contract Amount: (Before) KRW 241,973,146,733 → (After) KRW 517,856,145,079 (Increased by approx. KRW 275.9B)
- Contract Amount to Revenue Ratio: (Before) 5.32% → (After) 11.39%
- Contract Period End Date: (Before) December 31, 2030 → (After) December 31, 2033
- Disclosure Postponement Period: (Before) December 31, 2030 → (After) December 31, 2033
- Other Important Matters (Counterparty Disclosure Timeline): (Before) Scheduled for disclosure on December 31, 2030 → (After) Scheduled for disclosure on December 31, 2033
- Contract Overview (Post-Correction):
- Contract Title: Pharmaceutical Contract Manufacturing Agreement
- Contract Amount: KRW 517,856,145,079 (USD 375,693,663, increased by USD 200,147,271 from the previous USD 175,546,392, applied exchange rate KRW 1,378.40 per USD on the original filing date of May 23, 2025)
- Recent Annual Revenue: KRW 4,547,322,176,421 (Based on FY2024 consolidated financial statements)
- Contract Amount to Revenue Ratio: 11.39%
- Counterparty: Pharmaceutical company based in Europe
- Contract Period: May 23, 2025 – December 31, 2033
- Contract Date: May 23, 2025
- Other Important Investment Details:
- The contract end date and contract amount are subject to change upon mutual agreement.
- Counterparty identity is slated for disclosure on December 31, 2033, due to business confidentiality, subject to future changes.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Disclosure Timeline and Contract Updates Following Amount Increase and Postponement Extension
This correction disclosure reflects a major increase of approx. KRW 275.9B (USD 200,147,271) in contract value—expanding the contract ratio to 11.39% of revenue—along with a 3-year extension of the contract end date and confidentiality postponement period for the manufacturing deal with a European pharmaceutical company.
Monitoring potential further contract amount adjustments and checking official announcements aligned with the extended postponement date (December 31, 2033) is essential for tracking this agreement.
Relevant developments can be verified in future correction disclosures, filings upon expiration of the postponement period, and periodic reports.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
